207 related articles for article (PubMed ID: 29802086)
1. Uric acid is an independent predictor of cardiac allograft vasculopathy after heart transplantation.
Asleh R; Prasad M; Briasoulis A; Nardi V; Adigun R; Edwards BS; Pereira NL; Daly RC; Lerman A; Kushwaha SS
J Heart Lung Transplant; 2018 Sep; 37(9):1083-1092. PubMed ID: 29802086
[TBL] [Abstract][Full Text] [Related]
2. Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients.
Asleh R; Briasoulis A; Pereira NL; Edwards BS; Frantz RP; Daly RC; Lerman A; Kushwaha SS
J Heart Lung Transplant; 2018 Nov; 37(11):1372-1380. PubMed ID: 30174165
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients.
Asleh R; Briasoulis A; Kremers WK; Adigun R; Boilson BA; Pereira NL; Edwards BS; Clavell AL; Schirger JA; Rodeheffer RJ; Frantz RP; Joyce LD; Maltais S; Stulak JM; Daly RC; Tilford J; Choi WG; Lerman A; Kushwaha SS
J Am Coll Cardiol; 2018 Feb; 71(6):636-650. PubMed ID: 29420960
[TBL] [Abstract][Full Text] [Related]
4. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.
Asleh R; Briasoulis A; Pereira NL; Boilson BA; Edwards BS; Adigun R; Maltais S; Daly RC; Lerman A; Kushwaha SS
ESC Heart Fail; 2018 Dec; 5(6):1118-1129. PubMed ID: 30019530
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation.
Topilsky Y; Hasin T; Raichlin E; Boilson BA; Schirger JA; Pereira NL; Edwards BS; Clavell AL; Rodeheffer RJ; Frantz RP; Maltais S; Park SJ; Daly RC; Lerman A; Kushwaha SS
Circulation; 2012 Feb; 125(5):708-20. PubMed ID: 22207715
[TBL] [Abstract][Full Text] [Related]
6. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
Kobashigawa JA; Pauly DF; Starling RC; Eisen H; Ross H; Wang SS; Cantin B; Hill JA; Lopez P; Dong G; Nicholls SJ;
JACC Heart Fail; 2013 Oct; 1(5):389-99. PubMed ID: 24621971
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression.
Raichlin E; Bae JH; Kushwaha SS; Lennon RJ; Prasad A; Rihal CS; Lerman A
J Am Coll Cardiol; 2009 Apr; 53(15):1279-86. PubMed ID: 19358941
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus.
Potena L; Fearon WF; Sydow K; Holweg C; Luikart H; Chin C; Weisshaar D; Mocarski ES; Lewis DB; Valantine HA; Cooke JP
Transplantation; 2008 Mar; 85(6):827-33. PubMed ID: 18360263
[TBL] [Abstract][Full Text] [Related]
9. Circulating progenitor cells are associated with plaque progression and long-term outcomes in heart transplant patients.
Ozcan I; Toya T; Corban MT; Ahmad A; Loeffler D; Morse D; Lerman LO; Kushwaha SS; Lerman A
Cardiovasc Res; 2022 Jun; 118(7):1703-1712. PubMed ID: 34132771
[TBL] [Abstract][Full Text] [Related]
10. Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients.
Kittleson MM; Bead V; Fradley M; St John ME; Champion HC; Kasper EK; Russell SD; Wittstein IS; Hare JM
J Heart Lung Transplant; 2007 May; 26(5):498-503. PubMed ID: 17449420
[TBL] [Abstract][Full Text] [Related]
11. Invasive aortic pulse pressure is linked to cardiac allograft vasculopathy after heart transplantation.
Park HW; Ozcan I; Toya T; Ahmad A; Kanaji Y; Kushwaha SS; Lerman LO; Lerman A
Int J Cardiol; 2023 Jan; 370():167-174. PubMed ID: 36346255
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients.
Choi HI; Kang DY; Kim MS; Lee SE; Ahn JM; Lee JY; Kim YH; Park DW; Jung SH; Kim JJ
Atherosclerosis; 2022 Sep; 357():1-8. PubMed ID: 35981436
[TBL] [Abstract][Full Text] [Related]
13. Layered Fibrotic Plaques Are the Predominant Component in Cardiac Allograft Vasculopathy: Systematic Findings and Risk Stratification by OCT.
Clemmensen TS; Holm NR; Eiskjær H; Løgstrup BB; Christiansen EH; Dijkstra J; Barkholt TØ; Terkelsen CJ; Maeng M; Poulsen SH
JACC Cardiovasc Imaging; 2017 Jul; 10(7):773-784. PubMed ID: 28330670
[TBL] [Abstract][Full Text] [Related]
14. Fibrotic Plaque and Microvascular Dysfunction Predict Early Cardiac Allograft Vasculopathy Progression After Heart Transplantation: The Early Post Transplant Cardiac Allograft Vasculopathy Study.
Chih S; Chong AY; Džavík V; So DY; Aleksova N; Wells GA; Bernick J; Overgaard CB; Stadnick E; Mielniczuk LM; Beanlands RSB; Ross HJ
Circ Heart Fail; 2023 Jun; 16(6):e010173. PubMed ID: 37165901
[TBL] [Abstract][Full Text] [Related]
15. Attenuated-Signal Plaque Progression Predicts Long-Term Mortality After Heart Transplantation: IVUS Assessment of Cardiac Allograft Vasculopathy.
Okada K; Fearon WF; Luikart H; Kitahara H; Otagiri K; Tanaka S; Kimura T; Yock PG; Fitzgerald PJ; Yeung AC; Valantine HA; Khush KK; Honda Y
J Am Coll Cardiol; 2016 Jul; 68(4):382-92. PubMed ID: 27443435
[TBL] [Abstract][Full Text] [Related]
16. European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation.
Badano LP; Miglioranza MH; Edvardsen T; Colafranceschi AS; Muraru D; Bacal F; Nieman K; Zoppellaro G; Marcondes Braga FG; Binder T; Habib G; Lancellotti P;
Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):919-48. PubMed ID: 26139361
[TBL] [Abstract][Full Text] [Related]
17. Association of Aspirin Treatment With Cardiac Allograft Vasculopathy Progression and Adverse Outcomes After Heart Transplantation.
Asleh R; Briasoulis A; Smith B; Lopez C; Alnsasra H; Pereira NL; Edwards BS; Clavell AL; Stulak JM; Locker C; Kremers WK; Daly RC; Lerman A; Kushwaha SS
J Card Fail; 2021 May; 27(5):542-551. PubMed ID: 33962742
[TBL] [Abstract][Full Text] [Related]
18. Comparative Study of Pediatric Coronary Allograft Vasculopathy Between Single Centers in North America and United Kingdom.
Fenton M; Mahmood A; Burch M; Simmonds J; Kuhn MA
Transplant Proc; 2018 Dec; 50(10):3705-3709. PubMed ID: 30577259
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice.
Masetti M; Potena L; Nardozza M; Prestinenzi P; Taglieri N; Saia F; Pece V; Magnani G; Fallani F; Coccolo F; Russo A; Rapezzi C; Grigioni F; Branzi A
Am J Transplant; 2013 May; 13(5):1217-26. PubMed ID: 23621161
[TBL] [Abstract][Full Text] [Related]
20. Association of Endothelin-1 With Accelerated Cardiac Allograft Vasculopathy and Late Mortality Following Heart Transplantation.
Parikh RV; Khush K; Pargaonkar VS; Luikart H; Grimm D; Yu M; Okada K; Honda Y; Yeung AC; Valantine H; Fearon WF
J Card Fail; 2019 Feb; 25(2):97-104. PubMed ID: 30543947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
